Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: AN2 THERAPEUTICS, INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2022-09-20 to 2025-04-14
Current total value of award: $4957446
Description: DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR) BACTERIAL BIOTHREAT PATHOGENS.